GleamWall
中文EN

TLRY Tilray Brands, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1731348 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.9%
TTM net income YoY92.4%
TTM EPS YoY94.2%
Revenue 3-yr CAGR14.0%
Net income 3-yr CAGR—

Margins

Gross margin29.1%
Operating margin-9.3%
Net margin-17.1%
FCF margin—
EBITDA margin—

Returns

ROE-10.4%
ROA-7.4%
ROIC (approx.)-5.0%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.08x
Current ratio1.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.51x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-08-312026Q4*2026-05-312026Q32026-02-282026Q22025-11-302026Q12025-08-312025Q4*2025-05-312025Q32025-02-282025Q22024-11-30
Income statement
Revenue$257.15M$281.71M$206.73M$217.51M$209.50M$224.53M$185.78M$210.95M
Cost of revenue$179.64M$191.19M$151.78M$160.01M$152.03M$156.90M$133.77M$149.73M
Gross profit$77.51M$90.52M$54.95M$57.50M$57.47M$67.63M$52.01M$61.22M
R&D expense$89,000$180,000$62,000$78,000$41,000$34,000$85,000$60,000
SG&A expense$57.61M$61.17M$50.23M$51.17M$41.05M$37.97M$39.25M$46.00M
Operating income-$24.05M-$16.45M-$26.39M-$22.28M$2.09M-$1.44B-$759.93M-$42.22M
Pretax income-$38.31M-$24.07M-$23.26M-$39.96M-$772,000-$1.39B-$792.33M-$83.24M
Income tax$1.73M$13.86M$1.97M$3.55M-$2.29M-$125.14M$1.20M$2.04M
Net income-$43.14M-$49.57M-$26.57M-$44.93M-$322,000-$1.27B-$789.44M-$85.34M
EPS (basic)-0.32—-0.24-0.410.00—-8.69-0.99
EPS (diluted)-0.32—-0.24-0.410.00—-8.69-0.99
Weighted avg. shares (diluted)133.34M—112.68M110.34M106.03M—90.83M86.50M
Balance sheet
Cash & equivalents$214.96M$225.98M$204.62M$246.70M$264.83M$221.67M—$189.70M
Short-term investments$3.05M$5.29M$15.31M$44.85M$0$34.70M—$62.55M
Receivables$190.62M$189.17M$118.37M$109.07M$107.08M$121.49M—$112.74M
Inventory$328.97M$301.19M$292.30M$283.20M$282.79M$270.88M$263.40M$266.01M
Current assets$807.59M$792.13M$718.76M$729.32M$701.14M$688.63M—$707.34M
PP&E, net$665.92M$680.23M$543.01M$550.10M$680.23M$568.43M$537.80M$554.42M
Goodwill$752.35M$752.35M$752.35M$752.35M$752.35M$752.35M$1.30B$2.00B
Intangibles$42.47M$42.78M$23.34M$21.73M$25.17M$21.42M$847.22M$866.64M
Total assets$2.33B$2.33B$2.07B$2.10B$2.08B$2.07B—$4.19B
Current liabilities$430.69M$358.38M$257.54M$259.31M$267.63M$280.30M—$278.52M
Short-term debt$8.69M$8.78M$8.83M$8.57M$8.19M$7.18M—$17.75M
Long-term debt$118.05M$120.42M——————
Total debt$126.73M$129.20M——————
Total liabilities$721.28M$733.14M$549.12M$552.09M$561.99M$584.75M—$738.15M
Shareholders' equity$1.62B$1.61B$1.56B$1.58B$1.54B$1.51B$2.70B$3.47B
Net debt-$88.23M-$96.78M——————
Shares outstanding144.94M131.68M116.55M116.52M1.12B106.07M983.37M929.26M
Cash flow statement
Operating cash flow-$16.54M-$37.32M-$21.94M-$8.54M-$1.34M-$12.81M-$5.76M-$40.72M
Capital expenditure—————$6.33M$14.41M$5.44M
Free cash flow—————-$19.14M-$20.18M-$46.16M
Investing cash flow-$9.25M-$51.18M$28.92M-$58.01M$24.47M$13.52M-$119,000-$10.72M
Financing cash flow$13.97M$68.17M-$5.13M$48.10M$19.85M$16.64M$18.07M$38.20M
Stock-based compensation$6.58M$14.88M$13.72M$12.28M$5.05M$6.10M$4.04M$7.24M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.